These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33807106)

  • 1. Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation.
    Simon I; Perales S; Casado-Medina L; Rodríguez-Martínez A; Garrido-Navas MDC; Puche-Sanz I; Diaz-Mochon JJ; Alaminos C; Lupiañez P; Lorente JA; Serrano MJ; Real PJ
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33807106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
    Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q
    Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
    Bernemann C; Schnoeller TJ; Luedeke M; Steinestel K; Boegemann M; Schrader AJ; Steinestel J
    Eur Urol; 2017 Jan; 71(1):1-3. PubMed ID: 27471164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
    Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
    Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
    Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
    Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Zhu Y; Silberstein JL; Taylor MN; Maughan BL; Denmeade SR; Pienta KJ; Paller CJ; Carducci MA; Eisenberger MA; Luo J
    J Clin Oncol; 2017 Jul; 35(19):2149-2156. PubMed ID: 28384066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
    Antonarakis ES; Lu C; Wang H; Luber B; Nakazawa M; Roeser JC; Chen Y; Mohammad TA; Chen Y; Fedor HL; Lotan TL; Zheng Q; De Marzo AM; Isaacs JT; Isaacs WB; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    N Engl J Med; 2014 Sep; 371(11):1028-38. PubMed ID: 25184630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of
    Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
    Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AR-V7 as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A Hypothetical Cost-Saving Analysis.
    Pacheco-Orozco RA; Montealegre-Páez L; Cayol F; Martínez-Gregorio H; Oliver J; Frecha C; Vaca-Paniagua F; Perdomo S
    Oncologist; 2020 Dec; 25(12):e1990-e1995. PubMed ID: 32721059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer.
    To SQ; Kwan EM; Fettke HC; Mant A; Docanto MM; Martelotto L; Bukczynska P; Ng N; Graham LK; Parente P; Pezaro C; Mahon K; Horvath L; Todenhöfer T; Azad AA
    Eur Urol; 2018 Jun; 73(6):818-821. PubMed ID: 29398263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer.
    Zheng Z; Li J; Liu Y; Shi Z; Xuan Z; Yang K; Xu C; Bai Y; Fu M; Xiao Q; Sun H; Shao C
    Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.
    Qu F; Xie W; Nakabayashi M; Zhang H; Jeong SH; Wang X; Komura K; Sweeney CJ; Sartor O; Lee GM; Kantoff PW
    Clin Cancer Res; 2017 Feb; 23(3):726-734. PubMed ID: 27489290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
    Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
    Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.
    Hung J; Taylor AR; Divine GW; Hafron JM; Hwang C
    Clin Genitourin Cancer; 2016 Oct; 14(5):381-388. PubMed ID: 27157640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
    Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
    Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
    van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
    Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.